Updated:
Nautilus Biotechnology
Sujal Patel and Parag Mallick founded Nautilus Bio in 2016 to build a single-molecule proteomics platform targeting the scale of next-gen DNA sequencing.
Nautilus Biotechnology
Nautilus Biotechnology was founded in 2016 by Sujal Patel and Parag Mallick. Patel, a veteran of the data storage industry, had taken Isilon Systems public and then sold it to EMC, while Mallick is a Stanford associate professor whose lab focused on systems biology and personalized medicine. The company operates as a publicly traded development-stage entity, not a family office or asset manager; its wealth originates from venture capital and public market financing rather than a single-family fortune. Nautilus is developing a single-molecule protein analysis platform designed to deliver massive throughput. The scientific bet is that arrays of single-molecule protein attachments, imaged at high resolution with proprietary dyes and machine-learning-driven analysis, can quantify the proteome with the sensitivity and dynamic range that mass spectrometry cannot match at scale. The target application spans drug discovery, biomarker validation, and basic biological research. The company has disclosed partnerships with Amgen and the MD Anderson Cancer Center. Patents on its protein array and imaging chemistries form a core part of its intellectual property strategy. The commercial model will pair a hardware instrument sale with consumable reagent and software subscriptions. The firm went public via a SPAC merger with Arya Sciences Acquisition Corp III in June 2021, raising gross proceeds of roughly $345 million (per the firm, 2021). As a pre-revenue enterprise, Nautilus has since invested heavily in R&D and the buildout of its San Carlos headquarters. In October 2023, the company announced a restructuring and a realignment of its executive team, parting ways with its president of research and development, and naming Ken Suzuki as Chief Marketing Officer (per the firm, October 2023). The vendor's scientific advisory board includes Nobel laureate and synthetic biology pioneer Frances Arnold. Nautilus distinguishes itself by the ambition of its instrument architecture. Rather than competing for incremental share in the life science tools market, it is attempting to open a new category: routine, deep proteomics as a desktop-capable workflow. The company's structure as a publicly traded pure-play development entity means its execution timeline and capital consumption are fully visible — a governance posture uncommon in tools companies that typically start inside larger conglomerates or academic spinouts with limited transparency.
General information
Firm type
Unclassified
Year founded
2016
AUM
Undisclosed
Location
Region
North America
Country
United States
City
San Carlos
Corporate office
San Carlos, CA, United States
Principals
Sujal Patel
Co-Founder & CEO
Parag Mallick
Co-Founder & Chief Scientist
Sector focus
Frequently asked questions
Who runs the scientific direction at Nautilus Biotechnology?
Parag Mallick, the co-founder and Chief Scientist, leads the scientific vision for Nautilus. He is a tenured associate professor at Stanford University whose laboratory specialized in systems biology, mass spectrometry-based proteomics, and computational biomarker discovery. His academic work has focused on translating complex multi-omic data into clinical applications.
How is Nautilus Biotechnology funded?
Nautilus went public in June 2021 through a merger with a special-purpose acquisition company, Arya Sciences Acquisition Corp III, in a transaction that provided the company with roughly $345 million in gross proceeds. Prior to the SPAC, Nautilus was funded by venture investors including Vulcan Capital, Bezos Expeditions, and Andreessen Horowitz. As a public pre-revenue company, its operations are funded through cash on hand and periodic equity-linked financings.
How does Nautilus's proteomics technology differ from mass spectrometry?
Mass spectrometry identifies proteins indirectly by ionizing peptides and measuring mass-to-charge ratios, which inherently limits dynamic range and throughput. The Nautilus platform is designed to immobilize individual, intact protein molecules on a high-density array, label them with multi-affinity probe reagents, and image each molecule repeatedly. The company argues this single-molecule counting approach eliminates the dynamic-range compression and stochastic sampling problems that constrain mass spectrometry in complex samples.
When does Nautilus expect to launch its commercial product?
The company has not set a firm launch date for a commercial system. Nautilus has communicated that the platform is still in development and has shared select data at conferences from early-access collaborators. The restructuring announced in October 2023 refocused the development timeline, with the stated goal of bringing a robust instrument to market as engineering milestones are met rather than on a fixed calendar commitment.
Is Nautilus Biotechnology a private equity-backed company or a family office investment?
Neither. Nautilus is a publicly traded company listed on the Nasdaq under the ticker NAUT. It is a development-stage life science tools company, not a holding of a single-family office or a private equity portfolio company. Its shareholder base consists of institutional public-market investors and the venture funds that held pre-SPAC equity.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: